olaparib + rifampicin

**Olaparib + rifampicin** is not a fixed-dose combination product but refers to the concurrent administration of the two drugs. **Olaparib** is a small molecule PARP (poly(ADP-ribose) polymerase) inhibitor used primarily in the treatment of various cancers, notably ovarian and breast cancer, by interfering with DNA repair in cells with homologous recombination repair deficiency. **Rifampicin** is a potent antibiotic and a strong inducer of CYP3A4. When administered together, rifampicin significantly induces the metabolism of olaparib, leading to a marked reduction (around 87%) in olaparib’s systemic exposure, which can compromise its efficacy. The combination is generally contraindicated due to this strong pharmacokinetic interaction[1][3][5]. **Olaparib developer:** AstraZeneca. **Rifampicin developer:** Originally developed by the Italian company Lepetit.

Other names

olaparibrifampicinrifampin